AmtixBio

Innovative new drugs to overcome microbial infectious diseases

Gyeonggi-do, South Korea · Founded 2015 · $6.9M raised

Headquarters
Gyeonggi-do
Employees
11–50
Founded
2015
Business Model
B2B
Total Funding
$6.9M
Last Round
$5.4M Series CDec 2023
Rounds
2

About

AmtixBio is a South Korean global pharmaceutical company focused on developing innovative new drugs to overcome microbial infectious diseases and related conditions. The company's core pipeline targets antifungal treatments including nail and skin fungal infections, pulmonary mold infections, and multidrug-resistant Candida. AmtixBio's proprietary platforms — FADeR (functional amino acid derivative compound library), TARO Vault (multi-omics virulence factor database), and SAMH (sustained-release drug delivery) — enable a sustainable, first-in-class drug pipeline. The company also develops next-generation filler biomaterials.

Summary

AmtixBio is a Biotech company based in Gyeonggi-do, South Korea, founded in 2015. It has raised $6.9M in total across 2 rounds, most recently a $5.4M Series C round in Dec 2023.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series CSeries CDec 2023
$5.4M

Sign up to see all 2 rounds

Corporate Round through Series C — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AmtixBio on Indexed.vc
<a href="https://indexed.vc/companies/amtixbio"><img src="https://indexed.vc/api/badge/company/amtixbio" alt="AmtixBio on Indexed.vc" width="260" height="76" /></a>